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Background:  Angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) are indicated for patients with 
heart failure with reduced ejection fraction (HFrEF, EF <40%) but the tolerability of these agents may wane with advancing disease.
methods:  We studied 148 HFrEF admissions to an academic (Brigham and Women’s Hospital (BWH), =104) and community (Lancaster 
General Hospital (LGH), n=44) hospital. Patients were prospectively tracked in a Standardized Clinical Assessment and Management 
Program (SCAMP) that recommended discharge on same/greater doses of ACEi/ARB. Adherence, reasons for deviation and readmission 
rates were compared.
results:  On admission, 65% (n=68) at BWH and 56% (n=25) at LGH were on an ACEi/ARB. Among those admitted on ACEi/ARB, 69% 
(n=47) at BWH and 80% (n=20) at LGH were discharged on same/greater ACEi/ARB doses. The most common reasons for dose reduction 
were hypotension and renal dysfunction (see figure). Patients discharged on same/greater dose of ACEi/ARB had a 90-day readmission 
rate of 26% compared to 35% for those discharged on lower doses.
conclusion:  Despite guidance to maintain or increase ACEi/ARB dosing, 28% were discharged on lower doses, primarily due to 
hypotension and renal dysfunction. Independent of hospital setting, dose reduction was associated with higher readmission rates at 90 
days. Patients who require dose reduction during hospitalization may be a high-risk population that deserve closer surveillance post-
discharge.
